Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

This study compared the immunogenicity and safety of a booster dose of HepB-CpG (HEPLISAV-B® vaccine) with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in patients receiving chronic hemodialysis. This was a multicenter, randomized, open-label, phase 3 study of adults receiving hemodialysis with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Girndt, Matthias, Plüer, Manfred, Dellanna, Frank, Michelsen, Ann K., Beige, Joachim, Toussaint, Kai, Wehweck, Hubert J., Koch, Michael, Hafezi Rachti, Syrus, Faust, Justus, Bosselmann, Hans-Peter, Witzke, Oliver, Janssen, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Hepatitis – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746491/
https://www.ncbi.nlm.nih.gov/pubmed/36269938
http://dx.doi.org/10.1080/21645515.2022.2136912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746491/
https://www.ncbi.nlm.nih.gov/pubmed/36269938
http://dx.doi.org/10.1080/21645515.2022.2136912

Ejemplares similares